Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Boxed Warning Erased for Pfizer Smoking Cessation Aid Champix
July 10, 2017
- MSD, Bayer Yakuhin to Comarket Zetia-Statin Combo Drugs
July 10, 2017
- Maruho Takes Over Marketing Authorization for Astellas’ Protopic Ointment
July 10, 2017
- RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
- Konica Minolta Buying US Diagnostics Firm to Fully Enter Precision Medicine Biz
July 7, 2017
- Nippon Chemiphar Sounds Positive about Authorized Generic Biz
July 7, 2017
- Shire Japan Files Hereditary Angioedema Drug Icatibant
July 7, 2017
- AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race
July 7, 2017
- Meiji Seika Pharma Launches 1st AG with Meiact Generic
July 6, 2017
- Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations
July 6, 2017
- Daiichi Sankyo Drops Enbrel Biosimilar Development in Japan
July 6, 2017
- Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen
July 5, 2017
- Sumitomo Dainippon’s US Subsidiary Renamed
July 5, 2017
- J-TEC Wins Cultured Epidermis Order from Nagoya City Univ. Hospital
July 4, 2017
- French Biotech Oncodesign Set to Expand POC Services
July 4, 2017
- Aspen Japan to Take Over 4 Brands from Kyowa Kirin
July 4, 2017
- Sanofi Succeeds 4 Boehringer Brands in Japan under Global Asset Swap
July 4, 2017
- Signifor Filed for Cushing’s Disease in Japan: Novartis
July 4, 2017
- FDA Accepts NDA Resubmission for Sunovion’s COPD Med
July 4, 2017
- Evaluate Forecasts CAGR of 3.3% for Japan Market
July 4, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…